Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis

Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis.

A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Psoriasis is thought to arise from a combination of pathogenic factors including genetic susceptibility and environmental exacerbation. This article reviews the current status of guselkumab as a therapy for moderate-to-severe plaque psoriasis.

Update on Drugs and Drug News: March-April 2017

Drug update on Oxymetazoline hydrochloride 1% cream Rhofade™, Brodalumab for SC injection Siliq™, Cryolipolysis for upper arm fat reduction CoolAdvantage™, Petite applicator for CoolSculpting® Zeltiq®, Wound healing device WoundShiel™

Skin Treatments Introduced in 2016

The list covers new skin treatments for Actinic Keratosis, Hemangioma, Hidradenitis Suppurativa, as well as Anti-acne Agents, Antibacterial Agents, Anti-cancer Agents, Dermal Fillers, Neuromodulator and other treatments and drugs.

A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis

Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia. Interleukin (IL)-17 signaling has a central role in its pathogenesis, and is being looked at as a target. The rationale for IL-17 inhibitors, clinical trial results of new drugs like Brodalumab are included.

A Dermatologist’s Guide to Infection Screening Prior to Initiating Immunosuppressive Therapy

In this review, we summarize the most common immunosuppressant medications currently used in dermatology, and provide recommendations for infection screening prior to initiating treatment.

Update on Drugs and Drug News: January-February 2017

Update on drugs, approval dates, and comments for Nivolumab + ipilimumab (Opdivo® + Yervoy®), Etanercept for SC injection (Enbre®), Crisaborole 2% ointment (Eucrisa™ ), Hyaluronic acid dermal fillers Restylane® (Refyne Restylane® Defyne).

A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis

Recent advances in our understanding of the innate and adaptive immune systems have led to the identification of interleukin (IL)-17 as a key pro-inflammatory mediator in psoriasis. We review phase 1-3 clinical trials of ixekizumab, for treatment of moderate-to-severe plaque psoriasis.

Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis

Update and discussion on onychomycosis (nail fungus) and Efinaconazole 10%. Recent clinical trial results, and discussion about patient safety profile, special cases like diabetic patients, and cure rates.

Update on Drugs and Drug News: November-December 2016

Update on drugs, approval dates, and comments. Brodalumab for SC injection (Lumicef®), Etanercept-szzs for SC injection (Amjevita™), Propranolol hydrochloride oral solution 3.75 mg/ml (Hemangiol®), Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g foam (Enstilar®) are covered.

Update on Drugs and Drug News: September-October 2016

This update covers Pembrolizumab IV injection (Keytruda®), Hyaluronic acid gel filler (Juvéderm Volbella® XC), Biosimilar of infliximab (Flixabi®), Ceftaroline fosamil for IV infusion (Teflaro®), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® + Lidocaine), Ixekizumab SC injection (Talz®), Adapalene gel 0.1% (Differin® Gel), C1 esterase inhibitor(human) for IV infusion (Berinert®)

Rituximab: Uses in Dermatology

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Off-label use of rituximab, indications, side-effects, and dosing are some of the topics discussed.

Sodium Deoxycholate for Submental Contouring

Sodium Deoxycholate for contouring the jawlines are discussed. With recent approval in Canada (Belkyra™), and the US (Kybella®) for the treatment of submental fat, this is a timely review of this injectable. Clinical trial results, indications, safety and efficacy are discussed.

Update on Drugs and Drug News: July-August 2016

Update on Bilastine tablet (Blexten™), Ixekizumab SC injection (Talz®), Wound care gel (Lasercyn™ gel), Ceftaroline fosamil (Teflaro®), Nivolumab + ipilimumab (Opdivo® + Yervoy®), PDT for actinic keratosis (Ameluz® gel + BF-RhodoLED®)

Frontal Fibrosing Alopecia

Frontal fibrosing alopecia has become one of the most frequently seen causes of scarring alopecia at many specialist hair clinics. It has distinctive features and associations which distinguish it from LPP. Discussion includes familial or genetic factors, etiology, and trials.

Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa

Adalimumab (Humira®) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS). Discussion includes, safety and efficacy in clinical trials.

Update on Drugs and Drug News: May-June 2016

Update on Betamethasone dipropionate 0.05% spray (Sernivo™), Dapsone 7.5% gel (Aczone®), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Botulinum toxin type A for injection (Bocouture®), Calcipotriol + betamethasone dipropionate foam (Enstilar®), (Talz®), (Inflectra™), (Pruridexin™), and (Dermadexin™)

DSM-5 Update in Psychodermatology

This update summarizes current concepts, relevance, and therapeutics in psychodermatology, including aspects pertinent to depression, anxiety, obsessive-compulsive, impulse-control, and delusional disorders as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)

Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses

A topical formulation combining 0.5% 5-fluorouracil with 10% salicylic acid (5-FU-SA) was introduced in Europe under the trade name Actikerall™ for the treatment of AKs. Now commercially available in Canada, 5-FU-SA represents a patient applied therapeutic option. Clinical trial data is considered.

Update on Drugs and Drug News: March-April 2016

Update on (Beteflam™), Human papillomavirus (HPV) 9-valent vaccine, recombinant (Gardasil®9), (Imlygic®), Pembrolizumab IV injection (Keytruda®), Adalimumab SC injection (Humira®), Secukinumab SC injection (Cosentyx®), Ustekinumab SC injection (Stelara®), and Nivolumab + ipilimumab (Opdivo® + Yervoy®).

Skin Treatments Introduced in 2015

An overview and update of skin treatments introduced in 2015: Quick overview of drug name, indications and regulatory status. Deoxycholic acid injection, 5-fluorouracil 0.5% + salicylic acid 10% solution, Adapalene 0.3% + benzoyl peroxide 2.5% gel, and more are covered.

Nivolumab for Metastatic Melanoma

Melanoma is an aggressive skin cancer with a generally poor prognosis at Stage III-IV disease. Discussion centres around clinical trial data from phase I-III studies of Nivolumab (Opdivo®), a human monoclonal antibody which prevents immune inhibition by interacting with PD-1 on tumor cells.

Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature

Standard therapies for atopic dermatitis have fallen short, prompting efforts to discover novel therapeutics for this disease. Dupilumab, a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13, has shown promise.

Update on Drugs and Drug News: January-February 2016

January and February 2016: Update on drugs, approval dates, and comments. Autologous cell suspension (ReCell® ReGenerCell® ReNovaCell®), Calcipotriene 0.005% + betamethasone dipropionate 0.064% foam (Enstilar®), Ipilimumab (Yervoy®), Talimogene laherparepvec (T-Vec) oncolytic virus therapy (Imlygic™), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Dabrafenib + trametinib (Tafinlar® + Mekinist®), Nivolumab injection (Opdivo®) are covered.

Off-Label Uses of Topical Calcineurin Inhibitors

Topical calcineurin inhibitors (TCIs) have been proposed as an alternative, long-term treatment option to topical corticosteroids. Currently, TCIs are only approved for treatment of atopic dermatitis in patients 2 years of age or older. This article reviews the off-label uses of TCIs and their efficacy in the treatment of cutaneous diseases.

Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion

Treatment of PIH and melasma is challenging. There are no singular therapies that are efficacious on its own. Management, sun protection, topical lightening therapy and other treatment modalities are considered in this discussion on these growing concerns.

Update on Drugs and Drug News: November-December 2015

Update on Polidocanol 1% injectable foam (Varithena®), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Adalimumab SC injection (Humira®), Hyaluronic acid filler (Juvederm® Ultra XC), Nivolumab + ipilimumab (Opdivo® + Yervoy®), Ingenol mebutate gel (Picato®)

Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis

Onychomycosis is a stubborn fungal infection of the nails that can be difficult to manage. Clinical trial data of Tavaborole is considered, as it allows for effective nail penetration compared to ciclopirox and amorolfine lacquers.

Sugar Sag: Glycation and the Role of Diet in Aging Skin

Increased accumulation of AGEs in human tissue has been associated with serious medical concerns including end stage renal disease, chronic obstructive pulmonary disease, and, recently, skin aging. In this review, we summarize the evidence supporting the role of glycation in skin aging.

Update on Drugs and Drug News: September-October 2015

Update on Nivolumab IV infusion (Opdivo®), Pembrolizumab IV infusion (Keytruda®), Sonidegib phosphate capsules (Odomzo®), Azelaic acid 15% foam (Finacea® Foam), Adapalene 0.3% + benzoyl peroxide 2.5% gel (Epiduo® Forte), Deoxycholic acid injection (Belkyra™), Hyaluronic acid gel injectable dermal filler (Restylane® Lyft with Lidocaine), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® (+)

New Antibiotics in the Management of Acute Bacterial Skin and Skin Structure Infections

This article reviews the mechanism of action, efficacy, bacterial coverage, and potential side effects for dalbavancin and oritavancin, both semisynthetic lipoglycopeptide antibiotics, and tedizolid, an oxazolidinone.

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis

Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines. A review of clinical trial data treating psoriasis, considering adverse effects, efficacy and tolerance.

Update on Drugs and Drug News: July-August 2015

Update on Deoxycholic acid injection (Kybella™), Ivermectin 1% cream (Rosiver®), Adalimumab SC injection (Humira®), Apremilast tablets (Otezla®), and Dermal filler with calcium hydroxylapatite (CaHA) (Radiesse®)

Ivermectin 1% Cream for Rosacea

The etiology of papulopustular rosacea (PPR) is not well understood yet appears to involve both the innate and adaptive immune response in addition to possible infestation with Demodex mites. This article reviews data on Ivermectin cream 1%, a new topical treatment for PPR.

Hidradenitis Suppurativa: A Review with a Focus on Treatment Data

Hidradenitis suppurativa (HS) is a chronic disease of the follicular unit that often leads to marked impairment of quality of life. This article reviews various treatment modalities for HS including laser, surgery, retinoids, immunosuppression, biologics, and antibiotics.

Update on Drugs and Drug News: May-June 2015

Update on Varicose vein n-butyl-2-cyanoacrylate adhesive polymer (VenaSeal™ Closure System), Dermal filler + calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse®), Dalbavancin for IV injection (Xydalba™), Pembrolizumab for IV infusion (Keytruda®)

Current Management of Scalp Psoriasis

The scalp is involved in up to 80% of individuals with psoriasis. Topical treatment with corticosteroids with or without vitamin D3 analogues is the mainstay of treatment, but other therapies such as light treatment and systemic drugs including biologics are discussed.

Regulating Off-label Promotion of Medications: Has the Pendulum Swung Too Far?

Prescribing medications off-label is commonplace in dermatology. This article discusses the recent FDA policy chances, the debate on free speech, the benefits and risks of off label drug use and promotion, and how it relates to patient care.

Update on Drugs and Drug News: March-April 2015

Update on Human papillomavirus 9-valent vaccine, recombinant (Gardasil®9), Ivermectin 1% cream (Soolantra®), Naftifine HCl 2% gel & cream (Naftin®), Nivolumab IV infusion (Opdivo®), Polymethylmethacrylate collagen dermal filler for acne scars (Bellafill®), Secukinumab SC injection (Consentyx™).

Skin Treatments Introduced in 2014

An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.

POPULAR